RED BANK, New Jersey, BRUSSELS and MELBOURNE, Australia, July 30, 2012
/CNW/ - Ansell Ltd., a global leader in protection solutions, has today
introduced a ground-breaking new SENSOPRENE™ formulation, with the
launch of its GAMMEX® Non-Latex Accelerator-Free Sensitive surgical
glove. SENSOPRENE™ formulation is up to 30 per cent thinner than
standard surgical gloves to provide an unprecedented level of
sensitivity and comfort for healthcare workers worldwide.
Not only does SENSOPRENE™ technology deliver market-leading sensitivity,
it also provides advanced allergy protection. Free of both latex
proteins and chemical accelerators, the SENSOPRENE™ formulation reduces
the risk of both Type I (latex) and Type IV (chemical) allergies.
Clinical evidence reveals that 33 per cent of glove-related allergic
reactions in the medical sector are chemical-based* while 17 per cent
The GAMMEX® Non-Latex Accelerator-Free Sensitive surgical glove with
SENSOPRENE™ is a unique and complete solution, suitable for any
surgical need and all allergenic profiles. It addresses key end-user
requirements - fit, comfort, grip, strength, resistance, as well as
providing unrivalled sensitivity and allergy protection.
Commenting on the new SENSOPRENE™ formulation, Anthony B. Lopez,
President and General Manager of Ansell's Medical Global Business Unit
"For over 100 years, Ansell has delivered market-leading solutions, to
support and empower healthcare workers and protect patients worldwide.
An approach based on innovation and continual technological advancement
is key to our business. We were the first company to introduce an accelerator-free surgical glove and,
with SENSOPRENE™, we are again setting a new standard for allergy management in the
He continued, "With more than 100 million pairs of GAMMEX® surgical gloves used annually in hospitals worldwide, our insight is
second to none. We know and anticipate our end-users' requirements and continually strive to not just meet, but exceed them."
The GAMMEX® Non-Latex Accelerator-Free Sensitive glove with SENSOPRENE™
complies with all international standards. Ansell first introduced this
new glove in Europe and has plans to launch in Australia, New Zealand
and North America later this year.
* Types of eczema: hand dermatitis. EczemaNet Web site: http://skincarephysicians.com/eczemanet/hand_dermatitis.html. Updated December 7 2006. Accessed July 20 2011
** Filon FL. Bosco A. Fiorito A. Negro C. Barbina P. Latex symptoms and
sensitisation in healthcare workers. Int Arch Occup Environ Health.
2001: 74: 219-223
Ansell is a world leader in providing superior health and safety
protection solutions that enhance human wellbeing. With operations in
North America, Latin America, EMEA and Asia, Ansell employs more than
10,000 people worldwide and holds leading positions in the industrial
and medical gloves market, as well as in the sexual health and
wellbeing category worldwide. Ansell operates in four main business
segments: Medical Solutions, Industrial Solutions, Specialty Markets
and Sexual Wellness. Information on Ansell and its products can be
found at http://www.ansell.com.
SOURCE: Ansell Healthcare Europe nv
For further information:
David Graham, General Manager Finance & Treasury, Phone +61 3 9270 7215, email@example.com; EU Claire Keane, Edelman, Tel:(353)16789333, Claire.firstname.lastname@example.org